.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Cipla
McKinsey
Fuji
Boehringer Ingelheim
Argus Health
Federal Trade Commission
Baxter
Farmers Insurance
Colorcon

Generated: December 16, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 202150

« Back to Dashboard

NDA 202150 describes MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE, which is a drug marketed by Chartwell Rx, Glenmark Pharms, Heritage Pharms Inc, and Teva, and is included in four NDAs. It is available from four suppliers. Additional details are available on the MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE profile page.

The generic ingredient in MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE is hydrochlorothiazide; moexipril hydrochloride. There are thirty-one drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; moexipril hydrochloride profile page.

Summary for 202150

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Formulation / Manufacturing:see details

Pharmacology for NDA: 202150

Ingredient-typeThiazides
Mechanism of ActionAngiotensin-converting Enzyme Inhibitors
Physiological EffectIncreased Diuresis

Suppliers and Packaging for NDA: 202150

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; moexipril hydrochloride TABLET;ORAL 202150 ANDA Heritage Pharmaceuticals Inc. 23155-035 23155-035-05 500 TABLET, FILM COATED in 1 BOTTLE (23155-035-05)
MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE hydrochlorothiazide; moexipril hydrochloride TABLET;ORAL 202150 ANDA Heritage Pharmaceuticals Inc. 23155-035 23155-035-01 100 TABLET, FILM COATED in 1 BOTTLE (23155-035-01)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength12.5MG;7.5MG
Approval Date:Mar 7, 2014TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength12.5MG;15MG
Approval Date:Mar 7, 2014TE:ABRLD:No

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG;15MG
Approval Date:Mar 7, 2014TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
UBS
Deloitte
Moodys
QuintilesIMS
Medtronic
Fish and Richardson
Mallinckrodt
Fuji
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot